CAR-T Target Luciferase Reporter Cells: Tools for Validating CAR-T Effectors for Cancer Immunotherapy Webinar

Chimeric antigen receptor (CAR)-T cells have displayed remarkable efficacy in treating malignant cancers, particularly liquid tumors. Evaluating the biofunction of CAR-T cells in vitro typically involves a series of labor-intensive co-culture experiments and immunoassays, where reproducibility remains a challenge during the validation of new CAR-T cells due to donor-to-donor variations and other possible factors. In this webinar, we present new luciferase reporter tumor cell lines that naturally express high levels of clinically relevant CAR-T target antigens on cell surface, such as CD19, CD20 and HER2. Additionally, we show how these versatile reporter lines can be utilized to examine the function of CAR-T cells.

Key Points

• Luciferase reporter tumor cell lines naturally express high levels of clinically relevant CAR-T target antigens on cell surface, such as CD19, CD20 and HER2
• Our scientists engineered multiple ATCC authenticated tumor cell lines with common CAR-T target antigens to express the luciferase reporter
• The luciferase reporter system is a simple, robust, and highly sensitive means to measure biological processes and CAR-T cell cytotoxicity in a co-culture system
• ATCC scientists have tested that these luciferase reporter tumor cell lines can also be used in various CAR-T killing cancer ex vivo live cell imaging assays